To cite this paper use one of the standards below:
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains a major global health challenge, particularly due to the emergence of multidrug-resistant strains. Dihydrofolate reductase (DHFR) is an essential enzyme in folate metabolism and represents a promising target for the development of new antitubercular agents. In this study, we experimentally validated candidate MtbDHFR binders identified by Gain Therapeutics using their Magellan™ structure-based virtual screening platform. Recombinant MtbDHFR was heterologously expressed in Escherichia coli BL21(DE3) cells transformed with a pET28a vector harboring the target gene. The protein was purified from the soluble fraction by immobilized metal affinity chromatography followed by size-exclusion chromatography. A library of 96 candidate compounds was screened by differential scanning fluorimetry (DSF). Compounds exhibiting a melting-temperature shift (ΔTm) of ≥1°C above or below the MtbDHFR melting temperature (52.3°C) were considered potential hits. Twelve compounds were identified by DSF. Eleven increased the enzyme melting temperature, with ΔTm values ranging from 1.1°C to 2.4°C, whereas one compound produced a destabilizing shift of -4.5°C. Selected DSF hits were further evaluated in an enzymatic inhibition assay using dihydrofolate as substrate and NADPH as cofactor. Enzymatic activity was monitored by measuring NADPH consumption at 340 nm. Five compounds showed at least 50% inhibition of enzymatic activity and were subsequently characterized by isothermal titration calorimetry (ITC). The measured dissociation constants (Kd) ranged from 8.9 μM to 1.6 mM. The initial set comprised synthetically accessible compounds prioritized from the Enamine REAL chemical space. A follow-up series of 130 commercially available analogues of the initial hits was subsequently evaluated, yielding Kd values ranging from 52.5 μM to 1.8 mM. This work combines structure-based virtual screening with experimental biophysical and biochemical validation to identify starting points for the development of novel MtbDHFR inhibitors for tuberculosis treatment.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper